undisclosed RD cancers
Theseus Pharmaceuticals is designing kinase inhibitors for targeted cancer treatments. Cancer resistance occurs when cancerous cells mutate to circumvent the effect of a therapeutic. Resistance is commonly seen in therapies that target protein kinases. Theseus is outsmarting cancer resistance by developing next-generation tyrosine kinase inhibitors that offer more effective ways to treat cancer. Theseus’ approach involves using their unique drug discovery platform to develop pan-variant tyrosine kinase inhibitor therapies that uses chemical structure analyses with biomarker-guided design. Theseus’ lead candidate inhibitor, THE-630, has the potential to generate a robust and durable response in patients with gastrointestinal stromal tumors.